Prostate cancer: psychosocial implications and management

Bibliography

• 1  American Cancer Society: Cancer Facts and Figures. ACS, GA, USA (2007).
  Google Scholar
• 2  Penson DF, Litwin MS: Quality of life after treatment for prostate cancer. Curr. Urol. Rep.4,185–195 (2003).
  MedlineGoogle Scholar
• 3  Potosky AL, Davis WW, Hoffman RM et al.: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J. Natl Cancer Inst.96(18),1358–1367 (2004).
  MedlineGoogle Scholar
• 4  Klotz L: Active surveillance with selective delayed intervention is the way to manage ‘good risk’ prostate cancer. Natl Clin. Pract. Urol.2(3),136–142 (2005).
  MedlineGoogle Scholar
• 5  Eastham JA: Surgery insight: optimizing open nerve-sparing radical prostatectory techniques for improved outcomes. Natl Clin. Pract. Urol.4(10),561–569 (2007).
  MedlineGoogle Scholar
• 6  Eton DT, Lepore SJ: Prostate cancer and health-related quality of life: a review of the literature. Psychooncology11,307–326 (2002).
  MedlineGoogle Scholar
• 7  Zelefsky MJ, Fuks Z, Hunt M et al.: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys.53,1111–1116 (2002).
  MedlineGoogle Scholar
• 8  Chen RC, Clark JA, Manola J, Talcott JA: Treatment ‘mismatch’ in early prostate cancer: do treatment choices take patient quality of life into account? Cancer112(1),61–68 (2008).
  MedlineGoogle Scholar
• 9  Holzbeierlein JM, Castle E, Thrasher JB: Complications of androgen deprivation therapy: prevention and treatment. Oncology (Williston Park)18(3),303–309; discussion 310 (2004).
  MedlineGoogle Scholar
• 10  Herr HW, O’Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J. Urol.163(6),1743–1746 (2000).
  Medline CASGoogle Scholar
• 11  Thompson CA, Shanafelt TD, Loprinzi CL: Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist8(5),474–487 (2003).
  MedlineGoogle Scholar
• 12  Keating NL, O’Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol.24(27),4448–4456 (2006).
  Medline CASGoogle Scholar
• 13  D’Amico AV, Denham JW, Crook J et al.: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol.25(17),2420–2425 (2007).
  MedlineGoogle Scholar
• 14  Loblaw DA, Virgo KS, Nam R et al.: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol.25(12),1596–1605 (2007).
  Medline CASGoogle Scholar
• 15  Roth AJ, Kornblith AB, Batel-Copel L et al.: Rapid screening for psychologic distress in men with prostate cancer: a pilot study. Cancer82,1904–1908 (1998).
  Medline CASGoogle Scholar
• 16  Pirl WF, Siegel GI, Goode MJ, Smith MR: Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology11,518–523 (2002).
  MedlineGoogle Scholar
• 17  Litwin MS, Lubeck DP, Henning JM et al.: Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J. Urol.159,1988–1992 (1998).
  Medline CASGoogle Scholar
• 18  Ene KW, Nordberg G, Johansson FG, Sjöström B: Pain, psychological distress and health-related quality of life at baseline and 3 months after radical prostatectory. BMC Nurs.1,5–8 (2006).
  Google Scholar
• 19  Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott TA: Sexuality after treatment for early prostate cancer: exploring the meanings of “erectile dysfunction”. J. Gen. Intern. Med.16(10),649–655 (2001).
  Medline CASGoogle Scholar
• 20  Penson D, Mclerran D, Feng Z et al.: 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J. Urol.173(5),1701–1705 (2005).
  MedlineGoogle Scholar
• 21  Schover LR, Fouladi RT, Warneke CL et al.: Seeking help for erectile dysfunction after treatment for prostate cancer. Arch. Sex. Behav.33(5),443–454 (2004).
  MedlineGoogle Scholar
• 22  Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT: Factors predicting recovery of erections after radical prostatectomy. [see comment]. J. Urol.164(6),1929–1934 (2000).
  Medline CASGoogle Scholar
• 23  Schover LR, Fouladi RT, Warneke CL: Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer95(8),1773–1785 (2002).
  MedlineGoogle Scholar
• 24  Mulhall JP: Deciphering erectile dysfunction drug trials. J. Urol.170(2 Pt 1),353–358 (2003).
  MedlineGoogle Scholar
• 25  Dubbelman YD, Dohle GR, Schroder FH: Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur. Urol.50(4),711–718; discussion 718–720 (2006).
  MedlineGoogle Scholar
• 26  Walsh PC: Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J. Urol.163(6),1802–1807 (2000).
  Medline CASGoogle Scholar
• 27  Geary ES, Dendinger TE, Freiha FS, Stamey TA: Nerve sparing radical prostatectomy: a different view. J. Urol.154(1),145–149 (1995).
  Medline CASGoogle Scholar
• 28  Tsujimura A, Matsumiya K, Miyagawa Y et al.: Relation between erectile dysfunction and urinary incontinence after nerve-sparing and non-nerve-sparing radical prostatectomy. Urol. Int.73(1),31–35 (2004).
  MedlineGoogle Scholar
• 29  Mantz CA, Song P, Farhangi E et al.: Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.37(3),551–557 (1997).
  Medline CASGoogle Scholar
• 30  Brandeis JM, Litwin MS, Burnison CM, Reiter RE: Quality of life outcomes after brachytherapy for early stage prostate cancer. J. Urol.163(3),851–857 (2000).
  Medline CASGoogle Scholar
• 31  Huang GJ, Sadetsky N, Carroll P, Penson DF: Predictors of HRQOL during long-term follow-up of men treated for prostate cancer. Prostate Cancer Symposium. Orlando, FL, USA, 22–24 February 2007.
  Google Scholar
• 32  Montorsi F, Guazzoni G, Strambi LF et al.: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. [see comment]. J. Urol.158(4),1408–1410 (1997).
  Medline CASGoogle Scholar
• 33  Mulhall JP, Land S, Parker M, Waters WB, Flanigan RC: The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J. Sex. Med.2(4),532–540; discussion 540–542 (2005).
  Medline CASGoogle Scholar
• 34  Mulhall JP, Slovick R, Hotaling J et al.: Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J. Urol.167(3),1371–1375 (2002).
  MedlineGoogle Scholar
• 35  McCullough AR: Prevention and management of erectile dysfunction following radical prostatectomy. Urol. Clin. North Am.28(3),613–627 (2001).
  Medline CASGoogle Scholar
• 36  Kava BR, Yang Y, Soloway CT: Efficacy and patient satisfaction associated with penile prosthesis revision surgery. J. Sex. Med.4(2),509–518 (2007).
  MedlineGoogle Scholar
• 37  Schover LR: Sexuality and fertility after cancer. Hematology Am. Soc. Hematol. Educ. Program523–527 (2005).
  MedlineGoogle Scholar
• 38  Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS: Increased incidence of depressive symptoms in men with erectile dysfunction. Urology52(5),848–852 (1998).
  Medline CASGoogle Scholar
• 39  Araujo A, Durante R, Feldman HA, Goldstein I, McKinlay JB: The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom. Med.60(4),458–465 (1998).
  Medline CASGoogle Scholar
• 40  Nicolosi A, Moreira ED Jr, Villa M, Glasser DB: A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J. Affect. Disord.82(2),235–243 (2004).
  MedlineGoogle Scholar
• 41  Müller MJ, Ruof J, Graf-Morgentern M, Porst H, Benkert O: Quality of partnership in patients with erectile dysfunction after sildenafil treatment. Pharmacopsychiatry34(3),91–95 (2001).
  MedlineGoogle Scholar
• 42  Riley A, Riley E: Behavioural and clinical findings in couples where the man presents with erectile disorder: a retrospective study. Int. J. Clin. Pract.54(4),220–224 (2000).
  Medline CASGoogle Scholar
• 43  Krahn M, Ritvo P, Irvine J et al.: Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med. Care41(1),153–164 (2003).
  MedlineGoogle Scholar
• 44  Penedo FJ, Molton I, Dahn JR et al.: A randomized clinical trial of group-based cognitive–behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann. Behav. Med.31(3),261–270 (2006).
  MedlineGoogle Scholar
• 45  Dorey G: A clinical overview of the treatment of post-prostatectory incontinence. Br. J. Nurs.16(19),1194–1199 (2007).
  MedlineGoogle Scholar
• 46  Baum NH, Torti DC: Managing hot flashes in men being treated for prostate cancer. Geriatrics62(11),18–21 (2007).
  MedlineGoogle Scholar
• 47  Barton D, Loprinzi CL: Making sense of the evidence regarding nonhormonal treatments for hot flashes. Clin. J. Oncol. Nurs.8,39–42 (2004).
  MedlineGoogle Scholar
• 48  Naoe M, Ogawa Y, Shichijo T, Fuji K, Fukagai T, Yoshida H: Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis.9(3),275–278 (2006).
  Medline CASGoogle Scholar
• 49  Lajiness MJ: Megestrol acetate for the treatment of hot flashes in men undergoing hormone ablation therapy or orchiectomy. Urol. Nurs.27(6),556–557 (2007).
  MedlineGoogle Scholar
• 50  Carlsson S, Aus G, Wessman C, Hugosson J: Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) – results from a prospective, population-based, randomised study. Eur. J. Cancer43(14),2109–2116 (2007).
  MedlineGoogle Scholar
• 51  Roth AJ, Rosenfeld B, Kornblith AB et al.: The memorial anxiety scale for prostate cancer; validation of a new scale to measure anxiety in men with prostate cancer. Cancer97,2910–2918 (2003).
  MedlineGoogle Scholar
• 52  Roth AJ, Kornblith AB, Batel-Copel L et al.: Rapid screening for psychological distress in men with prostate cancer: a pilot study. Cancer82,1904–1908 (1998).
  Medline CASGoogle Scholar
• 53  Nelson CJ, Rosenfeld S, Roth AJ: Coping with your diagnosis and moving forward. In: American Cancer Society’s Complete Guide to Prostate Cancer. Bostwick DG, Crawford ED, Higano CS, Roach M (Eds). American Cancer Society Health Promotions, GA, USA, 81–88 (2005)
  Google Scholar
• 54  Canada AL, Neese LE, Sui D, Schover LR: Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer104(12),2689–2700 (2005).
  MedlineGoogle Scholar
• 55  Boehmer U, Clark JA: Communication about prostate cancer between men and their wives. J. Fam. Pract.50(3),226–223 (2001).
  Medline CASGoogle Scholar
• 56  Kornblith AB, Herr HW, Ofman US et al.: Quality of life of patients with prostate cancer and their spouses: the value of a database in clinical care. Cancer73,2791–2802 (1994).
  Medline CASGoogle Scholar
• 101  Us TOO International Prostate Cancer Education and Support Network www.ustoo.com/
  Google Scholar
• 102  American Cancer Society Man to Man program http://www.cancer.org/docroot/ESN/content/ESN_3_1X_Man_to_Man_36.asp?sitearea=SHR
  Google Scholar
• 103  Malecare website www.malecare.com/
  Google Scholar